Recruiting

AlphaReturn & AlphaVac

Sponsor:

Angiodynamics, Inc.

Code:

NCT07280247

Conditions

Pulmonary Embolism Acute

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AlphaReturn Blood Management System

Study Details

Brief summary:

The investigation is intended to evaluate the safety and effectiveness of the AlphaReturn Blood Management System when used in conjunction with the cleared AlphaVac MMA F1885 System for the treatment of acute pulmonary embolism.

Conditions

Pulmonary Embolism Acute

Study ID

NCT07280247

Start date

Mar 30, 2026

Status verified date

May, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

A potential subject will be included in the study if he/she meets all the following inclusion criteria:

1. Provision of signed and dated informed consent form.
2. Subject is 18 years of age and older.
3. Subject presents clinical signs and symptoms consistent with acute intermediate-risk pulmonary embolism for less than or equal to 14 days.
4. Subject has a diagnosis of pulmonary embolism detected from computed tomography angiography (CTA).
5. Subject has a RV/LV ratio of 0.9 or higher.
6. Subject has a systolic blood pressure (SBP) of 90mmHg or higher.
7. Subject has a heart rate of 130 beats per minute (BPM) or less prior to the procedure.
8. Subject is deemed medically eligible for interventional procedure(s) per institutional guidelines and/or clinical judgment.

Exclusion Criteria:

A potential subject will be excluded from the study if he/she meets any of the following exclusion criteria:

1. Subjects who are or may be pregnant as determined by a positive pregnancy test or who are breastfeeding.
2. Subjects who have any contraindication to systemic or therapeutic doses of heparin or anticoagulants.
3. Subjects who have used thrombolytics in the 30 days prior to the baseline CTA.
4. Subjects who have pulmonary hypertension with peak pulmonary artery pressure (PAP) > 70 mmHg.
5. Subjects who have FiO2 requirement > 44% or > 6 LPM to keep oxygen saturations > 90%.
6. Subjects with hematocrit < 28% within 6 hours of index procedure.
7. Subjects with platelets count < 100,000/μL.
8. Subjects with serum creatinine > 1.8 mg/dL.
9. Subjects with International Normalized Ratio (INR) > 3.
10. Subjects who have undergone a major trauma within the past 14 days of the index procedure and have Injury Severity Score (ISS) > 15.
11. Subjects with the presence of cancer requiring active chemotherapy.
12. Subjects with known bleeding diathesis or coagulation disorder.
13. Subjects who have had a cardiovascular or pulmonary surgery within the past 7 days of index procedure.
14. Subjects with a history of severe or chronic pulmonary hypertension, uncompensated heart failure, chest irradiation, underlying lung disease that is oxygen dependent, heparin-induced thrombocytopenia (HIT) and/or chronic left heart disease with left ventricular ejection fraction ≤ 30%.
15. Subjects with known anaphylactic reaction to radiographic contrast agents that cannot be pretreated.
16. Subject requires vasopressor after fluids to keep pressure ≥ 90mmHg.
17. Subjects with left bundle branch block.
18. Subjects who have intracardiac lead in the right ventricle or atrium.
19. Evidence such as imaging or other that suggest the subject is not appropriate for this procedure.
20. Subjects that have life expectancy < 90 days, in the opinion of the investigator at the time of enrollment.
21. Subjects dependent on extracorporeal life support such as extracorporeal membrane oxygenation (ECMO).
22. Participation in another investigational study.

Study Design

Enrollment

39 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: AlphaVac MMA F1885 System and AlphaReturn Blood Management System

Following mechanical thrombectomy using the AlphaVac MMA System, the treating physician will filter the aspirated blood using the AlphaReturn Blood Management System and reinfuse the filtered autologous blood back into the patient.

Interventions

AlphaReturn Blood Management System

The AlphaReturn Blood Management System allows for autologous injection of aspirated blood from an AlphaVac MMA System thrombectomy procedure.

Primary outcome measure

  • Rate of Device-Related Adverse Events (AEs) [ Time Frame: Through 30 days post-procedure ]
  • Rate of Technical Success [ Time Frame: Periprocedural ]

Central Contacts and Locations

Central contacts

Locations

CentraCare Heart and Vascular Center

Recruiting

Saint Cloud, Minnesota, United States, 56303

Contacts

Principal Investigator:

Brian Stegman, MD

University at Buffalo

Recruiting

Buffalo, New York, United States, 14203

Contacts

Principal Investigator:

David Zlotnick, MD

Jacobi Medical Center

Recruiting

The Bronx, New York, United States, 10461

Contacts

Principal Investigator:

Seth Sokol, MD

Kettering Health

Recruiting

Kettering, Ohio, United States, 45429

Contacts

Principal Investigator:

Ammar Safar, MD

Baylor Heart Hospital Plano

Recruiting

Plano, Texas, United States, 75093

Contacts

Principal Investigator:

Sameh Sayfo, MD

Methodist Healthcare

Recruiting

San Antonio, Texas, United States, 78229

Contacts

Principal Investigator:

Chandra Kunavarapu, MD

More Information

Sponsor

Angiodynamics, Inc.

Last update posted

May 11, 2026

Last verified

May, 2026

Keywords

  • pulmonary embolism
  • alphareturn

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Angiodynamics, Inc. on 2026-05-11.